Small molecule inhibitors of BRAF and MEK, a downstream protein immediately following BRAF, have been shown to confer a survival advantage for patients with <i>BRAF</i> <sup>V600E</sup> mutant advanced melanoma. The gene discussed is MAP2K7; the disease is melanoma.